Welcome to our dedicated page for Waters SEC filings (Ticker: WAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Waters Corporation (NYSE: WAT) filings with the U.S. Securities and Exchange Commission (SEC), along with AI-generated summaries to help interpret key disclosures. Waters files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that cover its operations in analytical instruments, separations technologies, and software serving the life, materials, food, and environmental sciences.
For Waters, 10-K and 10-Q filings are central resources for understanding its business segments, end markets, and risk factors. These documents discuss topics such as the company’s role in pharmaceutical, industrial, and academic/government applications, as well as its global footprint in over 100 countries. AI summaries can highlight sections related to recurring revenue, instrument trends, and investments in areas like bioanalytical characterization and bioseparations.
Form 8-K filings are particularly important for tracking material events. Recent 8-Ks describe quarterly financial results, provide press releases as exhibits, and outline the definitive agreements for a Reverse Morris Trust transaction that will combine BD’s Biosciences and Diagnostic Solutions business with Waters. Other 8-Ks discuss the effectiveness of registration statements on Form S-4 and Form 10 related to that transaction and the mailing of a proxy statement/prospectus to Waters shareholders.
Investors can also use this page to locate information on governance matters and potential insider activity through ownership reports referenced in Waters’ filings. Real-time updates from EDGAR, combined with AI-powered explanations, are intended to make complex regulatory documents more accessible by summarizing key terms, conditions, and implications for WAT shareholders and stakeholders following Waters’ evolution in life science and diagnostics markets.
Waters Corp. (WAT) Q2 2025 10-Q highlights
- Net sales: $771.3 m, up 8.9 % YoY; YTD $1.43 bn, +6.5 %.
- Mix: Product $473.4 m (+8.8 %), Service $297.9 m (+9.0 %).
- Profitability: Q2 operating income $188.2 m (24.4 % margin vs 26.7 %), essentially flat YoY. Net income $147.1 m (+3 %); diluted EPS $2.47 (vs $2.40). YTD EPS $4.50 (+9.2 %).
- Cash & debt: Cash $367 m (↑$42 m YTD); total debt $1.46 bn (↓$169 m). Current $260 m of notes re-classified as short-term; amended credit facility now $1.8 bn maturing 2030.
- Working capital: Inventories $541 m (+13 % since FY-end); A/R flat; deferred revenue up $113 m to $420 m.
- Cash flow: Operating cash flow $300.7 m (-5 % YoY); capex & software $48 m; free cash flow ~$253 m. Share buybacks limited to $14 m for RSU tax withholding.
- Acquisitions & strategy: Closed May 2025 purchase of Halo Labs for $35 m (adds particle-analysis tech). Subsequent event: definitive agreement (13 Jul 25) to acquire BD Biosciences & Diagnostic Solutions for ~$17.5 bn cash/stock—transformative if completed.
- Guidance: none provided; management notes FX headwinds, ERP roll-out ($130 m over 3 yrs) and higher tax rate (17.2 % vs 15.7 %).
- Balance-sheet strength: Equity $2.16 bn vs $1.83 bn FY-end; leverage (net debt/EBITDA) falls to ~2.7× pre-BD deal.
Overall, Waters delivered mid-single-digit growth and steady EPS, while preparing for a large, leverage-adding acquisition that could significantly reshape its scale and risk profile.
Waters Corporation (NYSE: WAT) filed an 8-K dated 4-Aug-2025. Under Item 2.02 the Company furnished, but did not file, a press release (Exhibit 99.1) detailing results for the quarter ended 28-Jun-2025; the actual revenue, EPS and margin figures are not included in the text of this report.
The filing also discloses preparations for a multi-step transaction involving Waters, Augusta SpinCo Corporation and Becton, Dickinson and Company. The parties plan to submit a Form S-4 (proxy/prospectus) and a Form 10 (information statement) to the SEC in connection with a spin-off of SpinCo from BD and its subsequent combination with Waters. Investors are urged to review those future documents when available.
No pro-forma financials, valuation terms, timing or regulatory approvals are provided at this stage. Apart from standard safe-harbor language and emerging-growth-company check-boxes, the only other material content is the exhibit list (99.1 press release; 104 Inline XBRL cover).
Waters Corporation (NYSE: WAT) filed an 8-K to disclose a material strategic transaction. The company has signed an agreement to combine Becton, Dickinson & Company’s (BD) Biosciences and Diagnostics Solutions business with Waters (the “Proposed Transaction”). No financial terms, deal value, or pro-forma forecasts were provided in the filing.
Key highlights
- Transaction scope: The combination would add BD’s Biosciences and Diagnostics Solutions unit to Waters’ existing analytical-instrument franchise, potentially expanding Waters’ end-market exposure from life-science research into clinical diagnostics.
- Communication timeline: A joint conference call and webcast was scheduled for 8:00 a.m. ET on 14 July 2025. The related press release (Ex. 99.1) and investor presentation (Ex. 99.2) are furnished—but not filed—under Regulation FD.
- Regulatory & shareholder approvals: Completion is subject to customary closing conditions, including Waters shareholder approval and multiple regulatory clearances.
- Forward-looking statements & risks: Waters lists 17 specific risk factors that could cause the deal to fail or the combined company to under-perform. Prominent risks include antitrust hurdles, integration complexity, cost overruns, talent retention, tax treatment, and potential litigation.
Accounting treatment: Because the information is furnished under Item 7.01 (Regulation FD) rather than 1.01 (Entry into a Material Definitive Agreement), it is not deemed “filed” for Section 18 liability.
Take-away: The announcement signals Waters’ intent to accelerate growth through a transformative acquisition, but material uncertainties remain until financial terms, financing structure, and regulatory feedback are disclosed.
Waters Corp. (NYSE: WAT) has filed a Form 4 indicating that director Wei Jiang acquired 68.35 common-stock units on 30 June 2025. The units were issued at a stated price of $0.00 because they represent deferred, stock-settled compensation in lieu of cash director fees under the company’s 1996 Non-Employee Director Deferred Compensation Plan. Each unit converts into one share of common stock on 1 January 2035, in line with the reporting person’s prior deferral election. Following the issuance, Jiang’s direct beneficial ownership rises to 2,478.57 shares. No derivative securities were bought or sold, and no shares were disposed of. The filing reflects a routine, low-dollar insider acquisition that marginally increases director equity alignment but is not material to Waters’ overall share count or valuation.
Waters Corp (WAT) filed a Form 4 on 26 June 2025 for insider Robert L. Carpio III, Senior Vice President of the Waters Division. On 24 June 2025, the company withheld 134 shares of common stock (transaction code F) at $346.80 per share to cover tax obligations associated with the vesting of previously granted restricted stock units. The withholding represents an estimated tax value of roughly $46.5 thousand. Following the transaction, Carpio directly owns 2,656 shares of WAT. No open-market trading or derivative activity was reported, indicating the event is administrative rather than strategic.